TNKase

News

Genentech has won FDA approval for its clot-buster TNKase as a treatment for acute ischaemic stroke, after almost abandoning the project in 2023.

News

Pulmonary fibrosis drug developer Avalyn prices its IPO at around $300m, as Seaport and Hemab both target $180m-plus from their listings.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.